Targeting allosteric disulphide bonds in cancer

Nature Reviews Cancer

Volumn 13, Issue 6, 2013, Pages 425-431

  Hogg, Philip J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BOSUTINIB; CYSTINE; DASATINIB; GLYCOPROTEIN GP 120; HYDROGEN PEROXIDE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLASMIN; POLYPEPTIDE; PROTEINASE ACTIVATED RECEPTOR 2; REACTIVE OXYGEN METABOLITE; THROMBOPLASTIN; VASCULOTROPIN; VASCULOTROPIN C; XRCC1 PROTEIN;

ALKYLATION; ALLOSTERISM; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DISTANT METASTASIS; DISULFIDE BOND; GLIOBLASTOMA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84878240943     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3519     Document Type: Review

References (93)

1. Walsh, C. T. Posttranslational Modification Of Proteins: Expanding Nature's Inventory (Roberts & Company, 2006).
2. Cook, K. M. & Hogg, P. J. Posttranslational control of protein function by disulfide bond cleavage. Antioxid. Redox Signal. 18, 1987-2015 (2013).
3. Braakman, I. & Bulleid, N. J. Protein folding and modification in the mammalian endoplasmic reticulum. Annu. Rev. Biochem. 80, 71-99 (2011).
4. Depuydt, M., Messens, J. & Collet, J. F. How proteins form disulfide bonds. Antioxid. Redox Signal. 15, 49-66 (2011).
5. Wong, J. W., Ho, S. Y. & Hogg, P. J. Disulfide bond acquisition through eukaryotic protein evolution. Mol. Biol. Evol. 28, 327-334 (2011).
6. Hogg, P. J. Disulfide bonds as switches for protein function. Trends Biochem. Sci. 28, 210-214 (2003).
7. Schmidt, B., Ho, L. & Hogg, P. J. Allosteric disulfide bonds. Biochemistry 45, 7429-7433 (2006).
8. Azimi, I., Wong, J. W. & Hogg, P. J. Control of mature protein function by allosteric disulfide bonds. Antioxid. Redox Signal. 14, 113-126 (2011).
9. Monod, J., Wyman, J. & Changeux, J. P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12, 88-118 (1965).
10. Schmidt, B. & Hogg, P. J. Search for allosteric disulfide bonds in NMR structures. BMC Struct. Biol. 7, 49 (2007).
11. Metcalfe, C., Cresswell, P. & Barclay, A. N. Interleukin-2 signalling is modulated by a labile disulfide bond in the CD132 chain of its receptor. Open Biol. 2, 110036 (2012).
12. Wang, M. Y. et al. A redox switch in C-reactive protein modulates activation of endothelial cells. FASEB J. 25, 3186-3196 (2011).
13. Jin, X. et al. Activation of extracellular transglutaminase 2 by thioredoxin. J. Biol. Chem. 286, 37866-37873 (2011).
14. Lay, A. J. et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408, 869-873 (2000).
15. Kaiser, B. K. et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482-486 (2007).
16. Zhou, A. et al. A redox switch in angiotensinogen modulates angiotensin release. Nature 468, 108-111 (2010).
17. Maekawa, A., Schmidt, B., Fazekas de St Groth, B., Sanejouand, Y. H. & Hogg, P. J. Evidence for a domain-swapped CD4 dimer as the coreceptor for binding to class II MHC. J. Immunol. 176, 6873-6878 (2006).
18. Ganderton, T., Wong, J. W., Schroeder, C. & Hogg, P. J. Lateral self-association of VWF involves the Cys2431-Cys2453 disulfide/dithiol in the C2 domain. Blood 118, 5312-5318 (2011).
19. Giannakopoulos, B. & Krilis, S. A. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 368, 1033-1044 (2013).
20. Ioannou, Y. et al. Naturally occurring free thiols within β2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 116, 1961-1970 (2010).
21. Ioannou, Y. et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum. 63, 2774-2782 (2011).
22. Passam, F. H. et al. Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J. Thromb. Haemost. 8, 1754-1762 (2010).
23. Passam, F. H. et al. β 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 116, 1995-1997 (2010).
24. Giannakopoulos, B. et al. Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. J. Autoimmun. 39, 121-129 (2012).
25. Crowley, S. D. & Coffman, T. M. Recent advances involving the renin-angiotensin system. Exp. Cell Res. 318, 1049-1056 (2012).
26. Jarvis, R. M., Hughes, S. M. & Ledgerwood, E. C. Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells. Free Radic. Biol. Med. 53, 1522-1530 (2012).
27. Cao, Z., Tavender, T. J., Roszak, A. W., Cogdell, R. J. & Bulleid, N. J. Crystal structure of reduced and of oxidized peroxiredoxin IV enzyme reveals a stable oxidized decamer and a non-disulfide-bonded intermediate in the catalytic cycle. J. Biol. Chem. 286, 42257-42266 (2011).
28. Fourquet, S., Guerois, R., Biard, D. & Toledano, M. B. Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J. Biol. Chem. 285, 8463-8471 (2010).
29. 2+/calmodulin-dependent protein kinase phosphatase (CaMKP) by oxidation/reduction at Cys-359. Arch. Biochem. Biophys. 526, 9-15 (2012).
30. Burgoyne, J. R. et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 317, 1393-1397 (2007).
31. Nadeau, P. J., Charette, S. J. & Landry, J. REDOX reaction at ASK1-Cys250 is essential for activation of JNK and induction of apoptosis. Mol. Biol. Cell 20, 3628-3637 (2009).
32. 2-terminal kinase activation and apoptosis. Mol. Biol. Cell 18, 3903-3913 (2007).
33. Wouters, M. A., Lau, K. K. & Hogg, P. J. Cross-strand disulphides in cell entry proteins: poised to act. Bioessays 26, 73-79 (2004).
34. Cerutti, N. et al. Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange. J. Biol. Chem. 285, 25743-25752 (2010).
35. Martin, G. et al. Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. J. Biol. Chem. 286, 21706-21716 (2011).
36. Algaier, I., Jakubowski, J. A., Asai, F. & von Kugelgen, I. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J. Thromb. Haemost. 6, 1908-1914 (2008).
37. Chmura, A. J., Orton, M. S. & Meares, C. F. Antibodies with infinite affinity. Proc. Natl Acad. Sci. USA 98, 8480-8484 (2001).
38. Sadowsky, J. D. et al. Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl Acad. Sci. USA 108, 6056-6061 (2011).
39. Groh, V. et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl Acad. Sci. USA 93, 12445-12450 (1996).
40. Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derivedγ δ T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879-6884 (1999).
41. Jinushi, M., Hodi, F. S. & Dranoff, G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl Acad. Sci. USA 103, 9190-9195 (2006).
42. Lohela, M., Bry, M., Tammela, T. & Alitalo, K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21, 154-165 (2009).
43. Saharinen, P., Eklund, L., Pulkki, K., Bono, P. & Alitalo, K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 17, 347-362 (2011).
44. Karkkainen, M. J. et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunol. 5, 74-80 (2004).
45. Baldwin, M. E. et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol. Cell. Biol. 25, 2441-2449 (2005).
46. Achen, M. G. & Stacker, S. A. Molecular control of lymphatic metastasis. Ann. NY Acad. Sci. 1131, 225-234 (2008).
47. He, Y. et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65, 4739-4746 (2005).
48. Toivanen, P. I. et al. Novel vascular endothelial growth factor D variants with increased biological activity. J. Biol. Chem. 284, 16037-16048 (2009).
49. Leppanen, V. M. et al. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood 117, 1507-1515 (2011).
50. Leppanen, V. M. et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl Acad. Sci. USA 107, 2425-2430 (2010).
51. Davydova, N. et al. Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies. Protein Expr. Purif. 82, 232-239 (2012).
52. Kim, L. C., Song, L. & Haura, E. B. Src kinases as therapeutic targets for cancer. Nature Rev. Clin. Oncol. 6, 587-595 (2009).
53. Okada, M., Nada, S., Yamanashi, Y., Yamamoto, T. & Nakagawa, H. CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J. Biol. Chem. 266, 24249-24252 (1991).
54. Okada, M. & Nakagawa, H. A protein tyrosine kinase involved in regulation of pp60c-src function. J. Biol. Chem. 264, 20886-20893 (1989).
55. Okada, M. & Nakagawa, H. Protein tyrosine kinase in rat brain: neonatal rat brain expresses two types of pp60c-src and a novel protein tyrosine kinase. J. Biochem. 104, 297-305 (1988).
56. Okada, M. & Nakagawa, H. Identification of a novel protein tyrosine kinase that phosphorylates pp60c-src and regulates its activity in neonatal rat brain. Biochem. Biophys. Res. Commun. 154, 796-802 (1988).
57. Bennett, B. D. et al. Identification and characterization of a novel tyrosine kinase from megakaryocytes. J. Biol. Chem. 269, 1068-1074 (1994).
58. Klages, S. et al. Ctk: a protein-tyrosine kinase related to Csk that defines an enzyme family. Proc. Natl Acad. Sci. USA 91, 2597-2601 (1994).
59. Kuo, S. S. et al. Identification and characterization of Batk, a predominantly brain-specific non-receptor protein tyrosine kinase related to Csk. J. Neurosci. Res. 38, 705-715 (1994).
60. McVicar, D. W. et al. Molecular cloning of lsk, a carboxyl-terminal src kinase (csk) related gene, expressed in leukocytes. Oncogene 9, 2037-2044 (1994).
61. Sakano, S. et al. Molecular cloning of a novel non-receptor tyrosine kinase, HYL (hematopoietic consensus tyrosine-lacking kinase). Oncogene 9, 1155-1161 (1994).
62. Cole, P. A., Shen, K., Qiao, Y. & Wang, D. Protein tyrosine kinases Src and Csk: a tail's tale. Curr. Opin. Chem. Biol. 7, 580-585 (2003).
63. Ia, K. K. et al. Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases. Growth Factors 28, 329-350 (2010).
64. Ogawa, A. et al. Structure of the carboxyl-terminal Src kinase, Csk. J. Biol. Chem. 277, 14351-14354 (2002).
65. Li, W., Young, S. L., King, N. & Miller, W. T. Signaling properties of a non-metazoan Src kinase and the evolutionary history of Src negative regulation. J. Biol. Chem. 283, 15491-15501 (2008).
66. Segawa, Y. et al. Functional development of Src tyrosine kinases during evolution from a unicellular ancestor to multicellular animals. Proc. Natl Acad. Sci. USA 103, 12021-12026 (2006).
67. Mills, J. E. et al. A novel disulfide bond in the SH2 Domain of the C-terminal Src kinase controls catalytic activity. J. Mol. Biol. 365, 1460-1468 (2007).
68. Kawabuchi, M. et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404, 999-1003 (2000).
69. Ingley, E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim. Biophys. Acta 1784, 56-65 (2008).
70. van den Berg, Y. W., Osanto, S., Reitsma, P. H. & Versteeg, H. H. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119, 924-932 (2012).
71. Ruf, W. Tissue factor and cancer. Thromb. Res. 130, S84-S87 (2012).
72. Gessler, F. et al. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience 165, 1312-1322 (2010).
73. Carneiro-Lobo, T. C. et al. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J. Thromb. Haemost. 7, 1855-1864 (2009).
74. Ryden, L. et al. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int. J. Cancer 126, 2330-2340 (2010).
75. Schaffner, F. et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 116, 6106-6113 (2010).
76. Ahamed, J. et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc. Natl Acad. Sci. USA 103, 13932-13937 (2006).
77. Chen, V. M. et al. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 45, 12020-12028 (2006).
78. Versteeg, H. H. et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 111, 190-199 (2008).
79. Metcalfe, C., Cresswell, P., Ciaccia, L., Thomas, B. & Barclay, A. N. Labile disulfide bonds are common at the leucocyte cell surface. Open Biol. 1, 110010 (2011).
80. Hotchkiss, K. A., Chesterman, C. N. & Hogg, P. J. Catalysis of disulfide isomerization in thrombospondin 1 by protein disulfide isomerase. Biochemistry 35, 9761-9767 (1996).
81. Casaletto, J. B. & McClatchey, A. I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nature Rev. Cancer 12, 387-400 (2012).
82. Bollag, G. et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Rev. Drug Discov. 11, 873-886 (2012).
83. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
84. Schenone, S., Brullo, C., Musumeci, F., Radi, M. & Botta, M. ATP-competitive inhibitors of mTOR: an update. Curr. Med. Chem. 18, 2995-3014 (2011).
85. Barneda-Zahonero, B. & Parra, M. Histone deacetylases and cancer. Mol. Oncol. 6, 579-589 (2012).
86. Lummis, S. C. et al. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature 438, 248-252 (2005).
87. Crawford, L. J., Walker, B. & Irvine, A. E. Proteasome inhibitors in cancer therapy. J. Cell Commun. Signal. 5, 101-110 (2011).
88. Frezza, M., Schmitt, S. & Dou, Q. P. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. Curr. Top. Med. Chem. 11, 2888-2905 (2011).
89. Romano, S. et al. The emerging role of large immunophilin FK506 binding protein 51 in cancer. Curr. Med. Chem. 18, 5424-5429 (2011).
90. Wiita, A. P. et al. Probing the chemistry of thioredoxin catalysis with force. Nature 450, 124-127 (2007).
91. Fersht, A. Enzyme Structure and Mechanism (Freeman, 1985).
92. Mor-Cohen, R. et al. Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIbβ3 and αvβ3 integrins in different manner. J. Biol. Chem. 287, 8879-8891 (2012).
93. Cuneo, M. J. & London, R. E. Oxidation state of the XRCC1 N-terminal domain regulates DNA polymerase β binding affinity. Proc. Natl Acad. Sci. USA 107, 6805-6810 (2010).